GlassScriptPhysician profile
Crystal M Trabel
NPI 1912480039
$857.26
in general payments reported to CMS, 2019-2025
17 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.74 · 2024: $355 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $137.50 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $89.31 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $85.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.62 | 2024-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $78.61 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $64.88 | 2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $64.15 | 2024-2025 | Glassia |
| United Therapeutics Corporation | $42.75 | 2025 | Tyvaso |
| Abbvie INC. | $37.74 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $37.03 | 2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $28.63 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $21.97 | 2025 | Winrevair |
| Pulmonx Corporation | $19.18 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $17.74 | 2024 | Acthar |
| Axsome Therapeutics, INC. | $17.27 | 2025 | Sunosi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $16.62 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $16.62 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Trabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.